Nakai S, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2004). Ther Apher Dial 2006; 10:476–497. doi: 10.1111/j.1744-9987.2006.00440.x
Chembo CL, et al. Long-term outcomes for primary glomerulonephritis: New Zealand glomerulonephritis study. Nephrology (Carlton) 2015; 20:899–907. doi: 10.1111/nep.12538
Murugapandian S, et al. Epidemiology of glomerular disease in southern Arizona: Review of 10-year renal biopsy data. Medicine (Baltimore) 2016; 95:e3633. doi: 10.1097/MD.0000000000003633
Haas M, et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol 2017; 28:691–701. doi: 10.1681/ASN.2016040433
Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368:2402–2414. doi: 10.1056/NEJMra1206793
Reid S, et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2011; CD003962. doi: 10.1002/14651858.CD003962.pub2
Selvaskandan H, et al. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol 2019; 23:577–588. doi: 10.1007/s10157-019-01700-1
Barratt J, Floege J. SGLT-2 inhibition in IgA nephropathy: The new standard of care? Kidney Int 2021; 100:24–26. doi: 10.1016/j.kint.2021.04.002
Wheeler DC, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100:215–224. doi: 10.1016/j.kint.2021.03.033
Pozzi C, et al. Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 1999; 353:883–887. doi: 10.1016/s0140-6736(98)03563-6
Manno C, et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24:3694–3701. doi: 10.1093/ndt/gfp356
Lv J, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 2009; 53:26–32. doi: 10.1053/j.ajkd.2008.07.029
Rauen T, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236. doi: 10.1056/NEJMoa1415463
Lv J, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2017; 318:432–442. doi: 10.1001/jama.2017.9362
Trimarchi H, et al. Oxford classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. Kidney Int 2017; 91:1014–1021. doi: 10.1016/j.kint.2017.02.003
Barbour SJ, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med 2019; 179:942–952. doi: 10.1001/jamainternmed.2019.0600
Chen T, et al. Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy. EBioMedicine 2020; 52:102657. doi: 10.1016/j.ebiom.2020.102657
Zhang X, et al. A validation study of crescents in predicting ESRD in patients with IgA nephropathy. J Transl Med 2018; 16:115. doi: 10.1186/s12967-018-1488-5
Schimpf JI, et al. Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores). BMC Nephrol 2018; 19:328. doi: 10.1186/s12882-018-1128-6
Roccatello D, et al. Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 2000; 15:833–835. doi: 10.1093/ndt/15.6.833
Kanno Y, et al. A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: Preliminary trial. Clin Exp Nephrol 2003; 7:48–51. doi: 10.1007/s101570300006